EMA launches procedure for manufacturers working with high-risk medical devices

News
Article

The European Medicines Agency's new standard procedure allows manufacturers to request advice from medical device expert panels

A scientist in a lab sits at a computer. He is looking at the screen of the computer, which is not visible to the camera. He wears glasses and a white lab coat. Image credit: ©PeakPoints/peopleimages.com – stock.adobe.com

The medical device expert panels are intended to foster innovation and provide faster patient access to devices. Image credit: ©PeakPoints/peopleimages.com – stock.adobe.com

The European Medicines Agency (EMA) has created a standard procedure for manufacturers of certain high-risk medical devices to request scientific advice on their intended clinical development strategy and proposals for clinical investigation. The announcement comes after the agency launched a pilot in February 2023, which has allowed them to establish this procedure and gather feedback from manufacturers and panel experts. The EMA created the new procedure in close collaboration with the European Commission.1

Now, manufacturers of class III devices and class IIb active devices designed to administer or remove medicines can submit their request for advice through a portal, as well as consult the medical device expert panels at different stages of clinical development. Currently, no fees are associated with these requests.

According to the European Commission, Class IIb devices are intended for long-term use, such as catheters, long-term corrective contact lenses and stents; class III devices are intended "to control, diagnose, monitor or correct" pathologies related to the heart, central circulatory system or central nervous system.2

The medical device expert panels will be an essential tool to foster innovation and provide faster patient access to safer and more effective devices. In the next few weeks, the EMA plan to publish a report of the pilot procedure and findings from the last 2 years.

Information on the submission process can be found on the EMA’s website.

Reference:

  1. EMA establishes regular procedure for scientific advice on certain high-risk medical devices. European Medicines Agency. Published February 10, 2025. Accessed February 10, 2025. https://www.ema.europa.eu/en/news/ema-establishes-regular-procedure-scientific-advice-certain-high-risk-medical-devices
  2. MDCG 2021-24 Guidance on classification of medical devices. Medical Device Coordination Group (MDCG). Updated October 2021. Accessed February 10, 2025. https://health.ec.europa.eu/system/files/2021-10/mdcg_2021-24_en_0.pdf

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.